Previa Medical

What Previa Medical does

Previa Medical SAS is a French healthtech company founded in 2020 and headquartered in Lyon that develops AI-powered digital biomarkers for the early prediction of life-threatening emergencies in hospitalized patients. Its PREVIA Platform analyzes structured clinical data — vital signs, laboratory results, medications, and medical history — in real time, integrates with hospital Electronic Health Records via FHIR/HL7 standards, and delivers configurable alerts through mobile, email, Microsoft Teams/Outlook, and DECT channels.

The commercially available core product is SEPSI Score, a Class IIb medical device software under EU MDR that predicts adult sepsis onset up to 48 hours before clinical symptoms, with reported performance of 85% sensitivity, 99% specificity, and 61% positive predictive value based on retrospective validation. Three additional modules are in development: AKI Score (acute kidney injury, funded by a €1.1M grant in October 2024 and co-developed with CHU Dijon), ARDS Score (acute respiratory distress syndrome, project phase), and ACR Score (cardiac arrest, project phase). The model is trained on 45,127 hospital stays and validated on 1,308 sepsis cases, with a peer-reviewed publication in Diagnostics (2025) and a European patent filed in 2022.

Previa Medical generates revenue through enterprise software licensing to hospitals and supplements R&D with grant funding. Distribution combines direct enterprise sales with catalog presence on UniHA/LOGIMED (1,465 member hospitals) and the NUMIH France store, alongside partnerships with Hospices Civils de Lyon, CHU Dijon, M2care, and French research institutes (CREATIS INSA Lyon, LIRIS CNRS). The company is privately held, has raised €2.1M in seed funding (February 2023) plus €1.1M in grant funding (October 2024), and has a 9-person core team plus a strategic committee, with planned U.S. expansion via the U.S. Market Gateway Accelerator for Medtech.

Name

Previa Medical

Legal name

PREVIA MEDICAL SAS

Website

https://previa-medical.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Previa Medical is a French healthtech company building AI-powered digital biomarkers that predict life-threatening hospital emergencies such as sepsis, serving hospitals and healthcare institutions via a Class IIb-certified platform integrated with EHR systems.

Ownership category

akta.pro rank

Product category

Predictive Healthcare Analytics Software

SIC

Services-Computer Integrated Systems Design (7373), Services-Computer Programming, Data Processing, Etc. (7370), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Sepsis, Deterioration & Rapid Response CDS (HLACAGAF)

akta.pro secondary industries

Risk Stratification, Early Warning Scores & Predictive Analytics (HLACAGAE), Interoperability Standards, Profiles & Implementation (HL7/FHIR/IHE) (HLACABAA)

Keywords

• Predictive healthcare analytics
• Sepsis detection software
• Digital biomarkers
• Clinical decision support
• AI medical devices

Headquarters

HQ city

Lyon

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Software Licensing/Subscription: Enterprise software licensing model for hospital deployment of digital biomarker solutions. SEPSI Score is classified as Class IIb medical device software. Revenue generated through licensing fees to healthcare institutions.
2. Research Grants: Grant funding supporting R&D activities, including €1.1M grant for AKI Score development announced October 2024.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Previa Medical develops AI-powered digital biomarker software that analyzes structured clinical data from hospital EHR systems in real time to predict the risk of life-threatening emergencies (sepsis, acute kidney injury, respiratory distress, cardiac arrest) in hospitalized patients. Its commercially available Class IIb medical device software, SEPSI Score, detects sepsis risk up to 48 hours before clinical symptoms appear, with additional modules (AKI, ARDS, ACR Scores) under development. The platform integrates with hospital information systems via FHIR/HL7 standards and issues alerts to clinicians.

Product overview

PREVIA MEDICAL offers a platform-plus-modules architecture centered on the PREVIA © Platform, which uses digital biomarkers powered by machine learning to predict and prevent four life-threatening hospital emergencies. The core product is the commercially available SEPSI Score © (Class IIb medical device) for early sepsis detection. Three additional modules are in development or project phases: AKI Score © for acute kidney injury (funded in 2024), ARDS Score © for respiratory distress, and ACR Score © for cardiac arrest. All modules share the same platform infrastructure and integrate with hospital EHR systems via FHIR/HL7 standards.

Differentiator

Problem solved

Functional benefit

Brands

• SEPSI Score: AI-based digital biomarker for early sepsis detection in hospitalized patients, capable of identifying patients at risk up to 48 hours before symptoms appear.
• AKI Score
• ARDS Score
• ACR Score
• PREVIA Platform

Products and services

• SEPSI Score Class IIb medical device software that predicts the risk of developing sepsis in hospitalized adult patients by analyzing structured clinical data from the Electronic Health Record in real time. Detects sepsis up to 48 hours before clinical signs appear, achieving 85% sensitivity, 99% specificity, and 61% positive predictive value.
• PREVIA Platform Central platform that analyzes patient data in real time using digital biomarkers and machine learning to predict and prevent life-threatening emergencies in hospital settings. Integrates with hospital EHR systems via FHIR/HL7 standards and delivers alerts through configurable channels including mobile, email, Microsoft Teams, and Outlook.
• AKI Score Predictive digital biomarker for acute kidney injury (AKI) that analyzes patient medical records and history in real time. In development with €1.1M grant funding from October 2024, intended to enable early intervention to protect kidney function and improve patient prognosis.

Quantifiable outcome

• 85% sensitivity, 99% specificity, 61% positive predictive value for sepsis prediction
• +3 more outcomes

Named customers4 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability2 records

Feature6 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• NUMIH FrancecoreChannel Partner/ Reseller/ Distributor · 1 October 2025Official partnership announced October 2025. PREVIA solutions are now referenced on NUMIH France store, affirming sovereignty, robustness, and reliability of technologies. Provides simplified integration with Sillage EHR platform. CEO Quentin François presented at NUMIH France Days conference on AI deployment in healthcare.
• CHU DijoncoreStrategic or Co-development Partner · 1 September 2025Unique partnership announced September 2025 for development of AKI prediction model. Analyzes over 100 medical data points including vital signs, medical history, and laboratory results. Goal is faster detection of critical situations and better patient care through early intervention.
• Hospices Civils de Lyon (HCL)coreStrategic or Co-development PartnerStrong collaboration with HCL teams. PREVIA presented to Minister of Health Stephanie Rist during her visit to HCL in February 2026, showcasing predictive medicine advances for sepsis and acute kidney failure detection.
• CREATIS INSA LyonminorStrategic or Co-development PartnerResearch collaboration with Institut National des Sciences Appliquées de Lyon. Co-authored ISBI 2025 paper on interpretability of deep learning models for sepsis prediction. Pierre-Elliott Thiboud conducts PhD research with this lab.
• LIRIS CNRSminorStrategic or Co-development PartnerResearch collaboration with LIRIS CNRS laboratories in Lyon for medical AI development and interpretability research.
• PulsalysminorStrategic or Co-development PartnerTechnology transfer and startup incubation organization in Lyon. Listed as partner supporting PREVIA's development ecosystem.
• LyonbiopoleminorStrategic or Co-development PartnerCompetitiveness cluster for biotech and health technologies in Lyon region. Listed as ecosystem partner supporting healthcare innovation.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Prenosis: US-based AI diagnostics company with FDA-cleared Sepsis ImmunoScore, a host-response based AI biomarker for early sepsis detection. Directly competes with Previa's SEPSI Score in the AI-driven early sepsis detection category for hospitalized patients.
• Inflammatix: Developer of host-response diagnostics including HostDx Sepsis for rapid infection/sepsis assessment at the point of care. Competes with Previa in the AI-enabled early sepsis detection market, addressing similar hospital customer use cases.
• Cytovale: Developer of IntelliSep, an FDA-cleared cellular biomarker test for sepsis diagnosis in emergency departments. Competes with Previa's SEPSI Score on the core proposition of faster, earlier sepsis detection in hospital settings.
• CLEW Medical: Israel-based provider of AI-powered predictive analytics for ICU and early detection of patient deterioration. Competes with Previa on AI-driven deterioration prediction using EHR data in hospital environments.
• Dascena: Developer of machine-learning algorithms for early prediction of sepsis and acute kidney injury in inpatient settings. Closely comparable product offering to Previa's SEPSI and AKI Scores.

Broad incumbents

• BioMérieux: Global in vitro diagnostics leader with extensive sepsis and infection diagnostics portfolio. Relevant as a broad incumbent that could integrate or compete with AI-driven sepsis detection solutions, and is connected to Previa via Sales Director Nouvelot's prior leadership.
• Philips (Philips HealthSuite/Patient Monitoring): Major medical technology incumbent offering patient monitoring, ICU analytics, and AI-augmented clinical decision support. Competes broadly with Previa's deterioration prediction platform across the same hospital customer base.
• GE HealthCare: Global medical imaging and monitoring incumbent expanding into AI-enabled patient monitoring and clinical analytics. Represents competitive and partnership risk for Previa in the hospital AI deterioration detection market.
• Edwards Lifesciences: Critical care leader with hemodynamic monitoring and AI-enabled clinical decision support for ICU. Represents a broader incumbent competing for hospital AI/CBS budgets relevant to Previa's sepsis, AKI, and cardiac arrest indications.

Emerging players

• MedAware: AI-driven patient safety platform focused on medication-related errors and clinical deterioration. Overlaps with Previa in applying AI to EHR data for early risk detection in hospitals, though targeting a different primary clinical risk.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/previa-medical

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Previa Medical